<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://www.appliedxl.com/news/regenxbio-surabgene-lomparvovec-sura-vec-abbv-rgx-314-nct03066258</loc>
    <news:news>
      <news:publication>
        <news:name>Biopharma News</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-19T09:05:49.913Z</news:publication_date>
      <news:title>REGENXBIO&apos;s sura-vec holds vision gains through 5 years in a 42-patient wet AMD cohort</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.appliedxl.com/news/perfusion-guided-fluid-resuscitation-acute-skin-failure</loc>
    <news:news>
      <news:publication>
        <news:name>Biopharma News</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-18T19:14:50.054Z</news:publication_date>
      <news:title>Perfusion-guided fluid strategy cuts skin failure in elderly ICU patients</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.appliedxl.com/news/novo-nordisk-denecimig-hemophilia-frontier4-nct05685238</loc>
    <news:news>
      <news:publication>
        <news:name>Biopharma News</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-18T19:35:12.265Z</news:publication_date>
      <news:title>Denecimig every-2-weeks dosing holds up in 26-week FRONTIER4 hemophilia A interim look</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.appliedxl.com/news/ropeginterferon-polycythemia-vera-dosing</loc>
    <news:news>
      <news:publication>
        <news:name>Biopharma News</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-18T20:24:47.031Z</news:publication_date>
      <news:title>Ropeginterferon analysis links faster dosing to quicker phlebotomy-free control in PV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.appliedxl.com/news/gcc-car-t-colorectal-cancer-phase1</loc>
    <news:news>
      <news:publication>
        <news:name>Biopharma News</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-17T19:24:53.314Z</news:publication_date>
      <news:title>GCC-targeted CAR-T shows 33% response rate in heavily pretreated colorectal cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.appliedxl.com/news/serum-biomarker-nsclc-immunotherapy</loc>
    <news:news>
      <news:publication>
        <news:name>Biopharma News</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-17T19:44:50.402Z</news:publication_date>
      <news:title>Serum three-protein score predicts immunotherapy response in NSCLC</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.appliedxl.com/news/dexmedetomidine-flurbiprofen-thyroidectomy-sleep</loc>
    <news:news>
      <news:publication>
        <news:name>Biopharma News</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-17T19:44:37.110Z</news:publication_date>
      <news:title>Opioid-free analgesia preserves melatonin, sleep after thyroidectomy in trial</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.appliedxl.com/news/hengrui-ivarmacitinib-hepatic-impairment-pk-nct04293029</loc>
    <news:news>
      <news:publication>
        <news:name>Biopharma News</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-17T20:05:28.362Z</news:publication_date>
      <news:title>Hepatic impairment leaves ivarmacitinib exposure largely unchanged, study finds</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.appliedxl.com/news/btk-inhibitor-venetoclax-mantle-cell-lymphoma</loc>
    <news:news>
      <news:publication>
        <news:name>Biopharma News</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-17T20:25:10.300Z</news:publication_date>
      <news:title>BTK inhibitor plus venetoclax lengthens survival in TP53-mutated mantle cell lymphoma</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.appliedxl.com/news/panoramic-norway-paxlovid-long-covid-nct05852873</loc>
    <news:news>
      <news:publication>
        <news:name>Biopharma News</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-17T21:44:58.054Z</news:publication_date>
      <news:title>Nirmatrelvir cut long COVID risk 26% vs 43% in stopped Norwegian trial</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.appliedxl.com/news/insmed-brinsupri-bronchiectasis-asian-subgroup-nct04594369</loc>
    <news:news>
      <news:publication>
        <news:name>Biopharma News</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-17T22:15:13.740Z</news:publication_date>
      <news:title>Brensocatib subgroup data show consistent effect in Asian ASPEN patients</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.appliedxl.com/news/oliceridine-intubation-anesthesia-readout</loc>
    <news:news>
      <news:publication>
        <news:name>Biopharma News</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-17T22:44:46.794Z</news:publication_date>
      <news:title>Oliceridine cut the remifentanil dose needed to blunt intubation response</news:title>
    </news:news>
  </url>
</urlset>
